Display options
Cite
Kobayashi N, Shimamura T, Tokuhisa M, et al. Sorafenib Monotherapy in a Patient with Unresectable Hepatic Epithelioid Hemangioendothelioma. Case Rep Oncol. 2016;9(1):134-7doi: 10.1159/000443986.
Kobayashi, N., Shimamura, T., Tokuhisa, M., Goto, A., & Ichikawa, Y. (2016). Sorafenib Monotherapy in a Patient with Unresectable Hepatic Epithelioid Hemangioendothelioma. Case reports in oncology, 9(1), 134-7. https://doi.org/10.1159/000443986
Kobayashi, Noritoshi, et al. "Sorafenib Monotherapy in a Patient with Unresectable Hepatic Epithelioid Hemangioendothelioma." Case reports in oncology vol. 9,1 (2016): 134-7. doi: https://doi.org/10.1159/000443986
Kobayashi N, Shimamura T, Tokuhisa M, Goto A, Ichikawa Y. Sorafenib Monotherapy in a Patient with Unresectable Hepatic Epithelioid Hemangioendothelioma. Case Rep Oncol. 2016 Feb 19;9(1):134-7. doi: 10.1159/000443986. eCollection 2016. PMID: 27293400; PMCID: PMC4899657.
Copy Download .nbib Format: NLM
Share it on

Case Rep Oncol. 2016 Feb 19;9(1):134-7. doi: 10.1159/000443986. eCollection 2016.

Sorafenib Monotherapy in a Patient with Unresectable Hepatic Epithelioid Hemangioendothelioma.

Case reports in oncology

Noritoshi Kobayashi, Takeshi Shimamura, Motohiko Tokuhisa, Ayumu Goto, Yasushi Ichikawa

Affiliations

  1. Department of Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  2. Shimamura Clinic, Kawasaki, Japan.

PMID: 27293400 PMCID: PMC4899657 DOI: 10.1159/000443986

Abstract

A 49-year-old Japanese man had multiple huge masses (max. size 60 mm diameter) in his liver. These tumors were pathologically diagnosed by tumor biopsy as epithelioid hemangioendotheliomas of the liver. In this case, multiple liver tumors existed in both lobes. Also this patient did not agree to receive surgical resection including liver transplantation. Chemotherapy with sorafenib at a dose of 400 mg/body twice a day was started. About 6 months later, CT findings revealed that these tumors were shrinking slightly; 33 months later, the tumors obviously showed a partial response in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST). Also 60 months later, the partial response continued with sorafenib monotherapy.

Keywords: Epithelioid hemangioendothelioma; Malignant liver tumor; Sorafenib

References

  1. Cancer. 2006 Nov 1;107(9):2108-21 - PubMed
  2. Cancer. 1999 Feb 1;85(3):562-82 - PubMed
  3. Cancer. 2013 Jul 15;119(14):2639-44 - PubMed
  4. Abdom Imaging. 2011 Aug;36(4):415-24 - PubMed
  5. Cancer. 1982 Sep 1;50(5):970-81 - PubMed

Publication Types